Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) have individually been shown to reduce cardiovascular and kidney outcomes in patients with T2DM, with a low hypoglycemia risk [3, 4]. Here, GLP1R is linked to type 2 diabetes mellitus.